Treatment Regimen Assessment — Aza-Ven for Adverse-Risk AML
Treatment Regimen Assessment — Aza-Ven for Adverse-Risk AML
[!note] This is a record-based assessment of what the documents show, not medical advice. All clinical decisions belong to the treating team (Bijay Prabhakaran Nair, Ashwin V Nair).
Overall Assessment
The regimen is well-chosen and showing measurable response, with several documentation and monitoring gaps that prevent fully confident assessment of response depth.
What's Working Well
1. Regimen Selection — Appropriate
Azacitidine + Venetoclax is standard-of-care for older/unfit AML patients. Ishamma (81F) with adverse-risk molecular features (RUNX1, ASXL1, SRSF2, STAG2, BCOR, NRAS) is squarely in the target population. Intensive chemotherapy is not appropriate given age and risk profile. The choice is guideline-concordant.
2. Measurable Treatment Response
- Day 21 BMBx: cellularity 60% → 25–30%, reticulin Grade 1–2 → 1 (Bone Marrow Biopsy 2025 12 31)
- Hb: 6.8 → 10.5 g/dL (Hemoglobin)
- WBC normalizing (5,400 on Apr 6)
- ANC: recovered above neutropenic threshold (2,590)
- ESR: 130 → 40 mm/hr (Elevated Esr)
3. Supportive Care — Appropriate
- Acyclovir prophylaxis: standard for VZV/HSV during venetoclax
- Posaconazole prophylaxis: standard antifungal + enables cost-effective venetoclax dose reduction via CYP3A4 inhibition
- Appropriate discontinuation of Pegfilgrastim after adverse reaction (bone pain)
4. Hepatic Tolerance — Excellent
Three LFT panels (Jan, Mar, Apr 2026) all normal despite triple hepatotoxic therapy (Lft). Reassuring for treatment continuation.
5. HbA1c Improvement
Diabetes Mellitus HbA1c 6.8% → 5.7% — though interpretation is complex with altered erythropoiesis and possible transfusion effects.
Concerns and Gaps
1. Drug Level Verification — NOT DONE (Critical Gap)
The venetoclax dosing strategy relies on posaconazole-mediated CYP3A4 inhibition boosting venetoclax exposure 5–8x. Neither venetoclax trough levels nor posaconazole trough levels have ever been measured. Hepatic resilience (Lft) raises the possibility of rapid CYP3A4 metabolism undermining this strategy. See Cyp3A4 Metabolizer Venetoclax Implications.
2. Venetoclax Duration Reduction — Rationale Undocumented
VEN went from 10 days (Cycle 2) → 5 days (Cycle 4+). Clinical rationale not documented. Response-guided? Toxicity-driven? Protocol-based? Without this context, it's unclear whether this reduction is appropriate or premature for an adverse-risk patient.
3. Exact Doses Unknown
No prescription documents ingested. Azacitidine dose (mg/m²) and venetoclax dose (mg) not confirmed. Cannot fully assess regimen without doses.
4. No MRD Monitoring
For adverse-risk AML with identifiable molecular targets (especially RUNX1), molecular MRD tracking after 2–3 cycles is recommended. No MRD testing documented. See Mrd Targets Explained.
5. Untreated Electrolyte Abnormalities
- Hyponatremia: persistent (Na 129–135), no workup (no serum/urine osmolality)
- Magnesium: 1.4 mg/dL (low), measured once, no supplementation documented
- Both compound fatigue and fall risk. See Qol Bang For Buck.
6. No G-CSF and ANC Monitoring Plan
Pegfilgrastim discontinued for bone pain. ANC nadir was 610 (Feb 17). Without G-CSF, prolonged neutropenia risk during future cycles. CBC monitoring plan not documented.
7. Non-Oncology Medications Unknown
DM medications (if any), antihypertensives, supplements — none documented. Complete medication reconciliation impossible.
8. No Response Assessment Schedule
Next bone marrow biopsy timing undefined. Milestones for adequate vs inadequate response not documented.
Summary Scorecard
| Domain | Assessment |
|---|---|
| Regimen selection | Appropriate — guideline-concordant for age/risk |
| Treatment response | Positive — morphologic and hematologic improvement |
| Supportive care | Good — appropriate prophylaxis |
| Dose verification | Gap — no drug levels, no prescription docs |
| Response monitoring | Gap — no MRD, no scheduled repeat BMBx |
| Electrolyte management | Gap — hyponatremia and hypomagnesemia unaddressed |
| Safety monitoring | Gap — no G-CSF plan, ANC monitoring unclear |
| Documentation completeness | Gap — doses, non-oncology meds, treatment plan unknown |
Most Actionable Items
- Obtain prescription documents with exact doses → add to
raw/prescriptions/ - Request venetoclax/posaconazole trough levels at next cycle
- Discuss MRD testing and response milestones with Dr. Bijay
- Workup hyponatremia (serum osm, urine osm, urine Na)
- Repeat magnesium and supplement if still low
Related Pages
- Aml | Active Medications | Venetoclax | Azacitidine | Posaconazole
- Lft | Hyponatremia | Magnesium | Hemoglobin | Sodium
- Cyp3A4 Metabolizer Venetoclax Implications | Mrd Targets Explained | Qol Bang For Buck
- Overview | Profile
[!note] This is a personal record-keeping analysis, not medical advice. Discuss all findings with the treating oncology team.
Filed: 2026-04-19.